دورية أكاديمية
أعرض في EDS

The roles of the kynurenine pathway in COVID-19 neuropathogenesis.

التفاصيل البيبلوغرافية
العنوان: The roles of the kynurenine pathway in COVID-19 neuropathogenesis.
المؤلفون: Dehhaghi M; Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia., Heydari M; Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Science, Tehran, Iran., Panahi HKS; Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia., Lewin SR; Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.; Victorian Infectious Diseases Service, The Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.; Department of Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, VIC, Australia., Heng B; Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia. benjamin.heng@mq.edu.au., Brew BJ; Peter Duncan Neurosciences Unit, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia. Bruce.Brew@svha.org.au.; Faculty of Medicine and Health, School of Clinical Medicine, UNSW Sydney, NSW, Australia. Bruce.Brew@svha.org.au.; Departments of Neurology and Immunology, St. Vincent's Hospital, Sydney, NSW, Australia. Bruce.Brew@svha.org.au.; University of Notre Dame, Darlinghurst, Sydney, NSW, Australia. Bruce.Brew@svha.org.au., Guillemin GJ; Peter Duncan Neurosciences Unit, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.; Department of Chemistry, Faculty of Mathematics and Natural Sciences, Institut Pertanian Bogor University, Bogor, Indonesia.
المصدر: Infection [Infection] 2024 May 27. Date of Electronic Publication: 2024 May 27.
Publication Model: Ahead of Print
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Springer Heidelberg Country of Publication: Germany NLM ID: 0365307 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1439-0973 (Electronic) Linking ISSN: 03008126 NLM ISO Abbreviation: Infection Subsets: MEDLINE
أسماء مطبوعة: Publication: 2011- : Heidelberg : Springer Heidelberg
Original Publication: München, Verlagsgesellschaft Otto Spatz.
مستخلص: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the highly contagious respiratory disease Corona Virus Disease 2019 (COVID-19) that may lead to various neurological and psychological disorders that can be acute, lasting days to weeks or months and possibly longer. The latter is known as long-COVID or more recently post-acute sequelae of COVID (PASC). During acute COVID-19 infection, a strong inflammatory response, known as the cytokine storm, occurs in some patients. The levels of interferon-γ (IFN-γ), interferon-β (IFN-β), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) are particularly increased. These cytokines are known to activate the enzyme indoleamine 2,3-dioxygenase 1 (IDO-1), catalysing the first step of tryptophan (Trp) catabolism through the kynurenine pathway (KP) leading to the production of several neurotoxic and immunosuppressive metabolites. There is already data showing elevation in KP metabolites both acutely and in PASC, especially regarding cognitive impairment. Thus, it is likely that KP involvement is significant in SARS-CoV-2 pathogenesis especially neurologically.
(© 2024. The Author(s).)
References: Ng LF, Hiscox JA. Coronaviruses in animals and humans. BMJ. 2020. https://doi.org/10.1136/bmj.m634 . (PMID: 10.1136/bmj.m634323766057201935)
Ortiz-Prado E, Simbaña-Rivera K, Gómez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, Muslin C, Jaramillo AMG, Barba-Ostria C, Cevallos-Robalino D. Clinical, molecular and epidemiological characterization of the SARS-CoV2 virus and the Coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020;98: 115094. (PMID: 32623267726056810.1016/j.diagmicrobio.2020.115094)
Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–92. (PMID: 3053194710.1038/s41579-018-0118-9)
Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25:278. (PMID: 32052514716977010.1111/tmi.13383)
Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining ‘host jump’of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 2015;23:468–78. (PMID: 26206723712558710.1016/j.tim.2015.06.003)
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2001017 . (PMID: 10.1056/NEJMoa20010173287757610777663)
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13. (PMID: 32007143713507610.1016/S0140-6736(20)30211-7)
Tian D, Ye Q. Hepatic complications of COVID-19 and its treatment. J Med Virol. 2020;92:1818–24. (PMID: 32437004728072510.1002/jmv.26036)
Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38:1504–7. (PMID: 32317203716510910.1016/j.ajem.2020.04.048)
Needham EJ, Chou SH-Y, Coles AJ, Menon DK. Neurological implications of COVID-19 infections. Neurocrit Care. 2020;32:667–71. (PMID: 32346843718845410.1007/s12028-020-00978-4)
Lawler NG, Gray N, Kimhofer T, Boughton B, Gay M, Yang R, Morillon A-C, Chin S-T, Ryan M, Begum S. Systemic perturbations in amine and kynurenine metabolism associated with acute SARS-CoV-2 infection and inflammatory cytokine responses. J Proteome Res. 2021;20:2796–811. (PMID: 3372483710.1021/acs.jproteome.1c00052)
Quist-Paulsen E, Aukrust P, Kran A-MB, Dunlop O, Ormaasen V, Stiksrud B, Midttun Ø, Ueland T, Ueland PM, Mollnes TE. High neopterin and IP-10 levels in cerebrospinal fluid are associated with neurotoxic tryptophan metabolites in acute central nervous system infections. J Neuroinflammation. 2018;15:1–14. (PMID: 10.1186/s12974-018-1366-3)
Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res. 2009;16:77–86. (PMID: 1952630110.1007/s12640-009-9051-z)
Guillemin GJ. Quinolinic acid: neurotoxicity. FEBS J. 2012;279:1355–1355. (PMID: 2225155210.1111/j.1742-4658.2012.08493.x)
Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, Hudson KE, Zimring JC, Hansen KC, Hod EA. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI insight. 2020. https://doi.org/10.1172/jci.insight.140327 . (PMID: 10.1172/jci.insight.140327333283867819746)
Cysique LA, Jakabek D, Bracken SG, Allen-Davidian Y, Heng B, Chow S, Dehhaghi M, Staats-Pires A, Darley DR, Byrne A, Phetsouphanh C, Kelleher A, Dore GJ, Matthews GV, Guillemin GJ, Brew BJ. Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study. Ann Clin Transl Neurol. 2022;10:1338–52. (PMID: 10.1002/acn3.51825)
Fernstrom JD. Role of precursor availability in control of monoamine biosynthesis in brain. Physiol Rev. 1983;63:484–546. (PMID: 613242110.1152/physrev.1983.63.2.484)
Marsh DM, Dougherty DM, Moeller FG, Swann AC, Spiga R. Laboratory-measured aggressive behavior of women: acute tryptophan depletion and augmentation. Neuropsychopharmacology. 2002;26:660. (PMID: 1192719110.1016/S0893-133X(01)00369-4)
Dehhaghi M, Kazemi Shariat Panahi H, Guillemin GJ. Microorganisms, tryptophan metabolism, and kynurenine pathway: a complex interconnected loop influencing human health status. Int J Tryptophan Res. 2019;12:1178646919852996. (PMID: 31258331658524610.1177/1178646919852996)
Dehhaghi M, Panahi HKS, Heng B, Guillemin GJ. The gut microbiota, kynurenine pathway, and immune system interaction in the development of brain cancer. Front Cell Dev Biol. 2020;19: 562812. (PMID: 10.3389/fcell.2020.562812)
Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001;78:842–53. (PMID: 1152090510.1046/j.1471-4159.2001.00498.x)
Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health. Science. 2017. https://doi.org/10.1126/science.aaf9794 . (PMID: 10.1126/science.aaf979428751584)
Stone TW. Does kynurenic acid act on nicotinic receptors? An assessment of the evidence. J Neurochem. 2020;152:627–49. (PMID: 3169375910.1111/jnc.14907)
Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478:197–203. (PMID: 2197602310.1038/nature10491)
Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012;279:1356–65. (PMID: 2224814410.1111/j.1742-4658.2012.08485.x)
Lugo-Huitrón R, Ugalde Muñiz P, Pineda B, Pedraza-Chaverrí J, Ríos C, Pérez-de la Cruz V. Quinolinic acid: an endogenous neurotoxin with multiple targets. Oxidative med cell longev. 2013. https://doi.org/10.1155/2013/104024 . (PMID: 10.1155/2013/104024)
La Cruz VP D, Carrillo Mora P, Santamaría A (2012) Quinolinic acid an endogenous molecule combining excitotoxicity oxidative stress and other toxic mechanisms. International Journal of Tryptophan Research. 5, IJTR-S8158.
Santamaría A, Galván-Arzate S, Lisý V, Ali SF, Duhart HM, Osorio-Rico L, Ríos C, Sut’astný F. Quinolinic acid induces oxidative stress in rat brain synaptosomes. NeuroReport. 2001;12:871–4. (PMID: 1127759910.1097/00001756-200103260-00049)
Kwidzinski E, Bechmann I. IDO expression in the brain: a double-edged sword. J Mol Med. 2007;85:1351–9. (PMID: 1759406910.1007/s00109-007-0229-7)
Robinson CM, Hale PT, Carlin JM. The role of IFN-γ and TNF-α-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res. 2005;25:20–30. (PMID: 1568461910.1089/jir.2005.25.20)
Babcock TA, Carlin JM. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor α in interferon-treated epithelial cells. Cytokine. 2000;12:588–94. (PMID: 1084373310.1006/cyto.1999.0661)
Robinson CM, Shirey KA, Carlin JM. Synergistic transcriptional activation of indoleamine dioxygenase by IFN-γ and tumor necrosis factor-α. J Interferon Cytokine Res. 2003;23:413–21. (PMID: 1367842910.1089/107999003322277829)
Campbell BM, Charych E, Lee AW, Möller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci. 2014;8:12. (PMID: 24567701391528910.3389/fnins.2014.00012)
Musso T, Gusella GL, Brooks A, Longo DL, Varesio L. Interleukin-4 inhibits indoleamine 2, 3-dioxygenase expression in human monocytes. Blood. 1994. https://doi.org/10.1182/blood.V83.5.1408.bloodjournal8351408 . (PMID: 10.1182/blood.V83.5.1408.14088193369)
Gál EM, Sherman AD. l-Kynurenine Its synthesis and possible regulatory function in brain. Neurochem Res. 1980;5:223–39. (PMID: 615490010.1007/BF00964611)
Badawy AA. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int j tryptophan res. 2017;10:1178646917691938. (PMID: 28469468539832310.1177/1178646917691938)
Oxenkrug GF. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan—kynurenine metabolism. Ann N Y Acad Sci. 2010;1199:1–14. (PMID: 2063310410.1111/j.1749-6632.2009.05356.x)
Martin-Gallausiaux C, Larraufie P, Jarry A, Béguet-Crespel F, Marinelli L, Ledue F, Reimann F, Blottière HM, Lapaque N. Butyrate produced by commensal bacteria down-regulates indolamine 2, 3-dioxygenase 1 (IDO-1) expression via a dual mechanism in human intestinal epithelial cells. Front Immunol. 2018;9:2838. (PMID: 30619249629783610.3389/fimmu.2018.02838)
Vujkovic-Cvijin I, Swainson LA, Chu SN, Ortiz AM, Santee CA, Petriello A, Dunham RM, Fadrosh DW, Lin DL, Faruqi AA. Gut-resident Lactobacillus abundance associates with IDO1 inhibition and Th17 dynamics in SIV-infected macaques. Cell Rep. 2015;13:1589–97. (PMID: 26586432478296810.1016/j.celrep.2015.10.026)
Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, Li T, Yin Y. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol. 2018;8:13. (PMID: 29468141580820510.3389/fcimb.2018.00013)
Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S. Short chain fatty acids and its producing organisms: an overlooked therapy for IBD? EBioMedicine. 2021. https://doi.org/10.1016/j.ebiom.2021.103293 . (PMID: 10.1016/j.ebiom.2021.103293338131348047503)
Alberati-Giani D, Ricciardi-Castagnoli P, Köhler C, Cesura AM. Regulation of the kynurenine metabolic pathway by interferon-γ in murine cloned macrophages and microglial cells. J Neurochem. 1996;66:996–1004. (PMID: 876985910.1046/j.1471-4159.1996.66030996.x)
Zunszain PA, Anacker C, Cattaneo A, Choudhury S, Musaelyan K, Myint AM, Thuret S, Price J, Pariante CM. Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology. 2012;37:939–49. (PMID: 2207187110.1038/npp.2011.277)
Hayes AJ, Zheng X, O’Kelly J, Neyton LP, Bochkina NA, Uings I, Liddle J, Baillie JK, Just G, Binnie M. Kynurenine monooxygenase regulates inflammation during critical illness and recovery in experimental acute pancreatitis. Cell Rep. 2023. https://doi.org/10.1016/j.celrep.2023.112763 . (PMID: 10.1016/j.celrep.2023.1127633798056410872270)
Hutchinson JP, Rowland P, Taylor MR, Christodoulou EM, Haslam C, Hobbs CI, Holmes DS, Homes P, Liddle J, Mole DJ. Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Nat Commun. 2017;8:15827. (PMID: 28604669547754410.1038/ncomms15827)
Liddle J, Beaufils B, Binnie M, Bouillot A, Denis AA, Hann MM, Haslam CP, Holmes DS, Hutchinson JP, Kranz M. The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis. Bioorg Med Chem Lett. 2017;27:2023–8. (PMID: 2833614110.1016/j.bmcl.2017.02.078)
Baumgartner R, Berg M, Matic L, Polyzos K, Forteza M, Hjorth SA, Schwartz TW, Paulsson-Berne G, Hansson G, Hedin U. Evidence that a deviation in the kynurenine pathway aggravates atherosclerotic disease in humans. J Intern Med. 2021;289:53–68. (PMID: 3279423810.1111/joim.13142)
Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O’Mahony L, Palomares O. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011. https://doi.org/10.1016/j.jaci.2010.11.050 . (PMID: 10.1016/j.jaci.2010.11.05022051696)
Papadimitriou C, Celikkaya H, Cosacak MI, Mashkaryan V, Bray L, Bhattarai P, Brandt K, Hollak H, Chen X, He S. 3D culture method for Alzheimer’s disease modeling reveals interleukin-4 rescues Aβ42-induced loss of human neural stem cell plasticity. Dev cell. 2018. https://doi.org/10.1016/j.devcel.2018.06.005 . (PMID: 10.1016/j.devcel.2018.06.00529974866)
Cherian AK, Gritton H, Johnson DE, Young D, Kozak R, Sarter M. A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats. Neuropharmacology. 2014;82:41–8. (PMID: 437226410.1016/j.neuropharm.2014.03.004)
Blanco-Ayala T, Sathyasaikumar K, Uys J, Perez-De-La-Cruz V, Pidugu L, Schwarcz R. N-acetylcysteine inhibits kynurenine aminotransferase II. Neuroscience. 2020;444:160–9. (PMID: 3276861710.1016/j.neuroscience.2020.07.049)
Mondanelli G, Iacono A, Carvalho A, Orabona C, Volpi C, Pallotta MT, Matino D, Esposito S, Grohmann U. Amino acid metabolism as drug target in autoimmune diseases. Autoimmun Rev. 2019;18:334–48. (PMID: 3079794310.1016/j.autrev.2019.02.004)
Mándi Y, Vécsei L. The kynurenine system and immunoregulation. J Neural Transm. 2012;119:197–209. (PMID: 2174405110.1007/s00702-011-0681-y)
Harden JL, Egilmez NK. Indoleamine 2, 3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest. 2012;41:738–64. (PMID: 23017144364591210.3109/08820139.2012.676122)
Bracho-Sanchez E, Hassanzadeh A, Brusko MA, Wallet MA, Keselowsky BG. Dendritic cells treated with exogenous indoleamine 2, 3-dioxygenase maintain an immature phenotype and suppress antigen-specific T cell proliferation. J immunol regen med. 2019;5: 100015. (PMID: 317885806884339)
Fallarino F, Vacca C, Orabona C, Belladonna ML, Bianchi R, Marshall B, Keskin DB, Mellor AL, Fioretti MC, Grohmann U. Functional expression of indoleamine 2, 3-dioxygenase by murine CD8α+ dendritic cells. Int Immunol. 2002;14:65–8. (PMID: 1175175310.1093/intimm/14.1.65)
Shortman K, Liu Y-J. Mouse and human dendritic cell subtypes. Nat Rev Immunol. 2002;2:151–61. (PMID: 1191306610.1038/nri746)
Reizis B. Plasmacytoid dendritic cells: development, regulation, and function. Immunity. 2019;50:37–50. (PMID: 30650380634249110.1016/j.immuni.2018.12.027)
Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev. 2010;234:142–62. (PMID: 20193017350743410.1111/j.0105-2896.2009.00881.x)
Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563–604. (PMID: 2351698510.1146/annurev-immunol-020711-074950)
Sichien D, Lambrecht B, Guilliams M, Scott C. Development of conventional dendritic cells: from common bone marrow progenitors to multiple subsets in peripheral tissues. Mucosal Immunol. 2017;10:831–44. (PMID: 2819836510.1038/mi.2017.8)
Kalantari T, Kamali-Sarvestani E, Ciric B, Karimi MH, Kalantari M, Faridar A, Xu H, Rostami A. Generation of immunogenic and tolerogenic clinical-grade dendritic cells. Immunol Res. 2011;51:153–60. (PMID: 22105838347433010.1007/s12026-011-8255-5)
Stone TW, Williams RO. Modulation of T cells by tryptophan metabolites in the kynurenine pathway. Trends Pharmacol Sci. 2023. https://doi.org/10.1016/j.tips.2023.04.006 . (PMID: 10.1016/j.tips.2023.04.00637248103)
Jurado-Manzano BB, Zavala-Reyes D, Turrubiartes-Martínez EA, Portales-Pérez DP, González-Amaro R, Layseca-Espinosa E. FICZ generates human tDCs that induce CD4+ CD25high Foxp3+ treg-like cell differentiation. Immunol Lett. 2017;190:84–92. (PMID: 2876507110.1016/j.imlet.2017.07.013)
Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176:6752–61. (PMID: 1670983410.4049/jimmunol.176.11.6752)
Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008;8(5):337–48. (PMID: 1840873510.1038/nri2295)
Wang X-F, Wang H-S, Wang H, Zhang F, Wang K-F, Guo Q, Zhang G, Cai S-H, Du J. The role of indoleamine 2, 3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. Cell Immunol. 2014;289:42–8. (PMID: 2472111010.1016/j.cellimm.2014.02.005)
Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93:250–6. (PMID: 3259250110.1002/jmv.26232)
Fara A, Mitrev Z, Rosalia RA, Assas BM. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biol. 2020;10: 200160. (PMID: 32961074753608410.1098/rsob.200160)
Fraser DD, Slessarev M, Martin CM, Daley M, Patel MA, Miller MR, Patterson EK, O’Gorman DB, Gill SE, Wishart DS. Metabolomics profiling of critically ill coronavirus disease 2019 patients: identification of diagnostic and prognostic biomarkers. Crit Care Explor. 2020. https://doi.org/10.1097/CCE.0000000000000272 . (PMID: 10.1097/CCE.0000000000000272331349537587450)
Lionetto L, Ulivieri M, Capi M, De Bernardini D, Fazio F, Petrucca A, Pomes LM, De Luca O, Gentile G, Casolla B. Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2021. https://doi.org/10.1016/j.bbadis.2020.166042 . (PMID: 10.1016/j.bbadis.2020.16604233338598)
Marín-Corral J, Rodríguez-Morató J, Gomez-Gomez A, Pascual-Guardia S, Muñoz-Bermúdez R, Salazar-Degracia A, Pérez-Terán P, Restrepo MI, Khymenets O, Haro N. Metabolic signatures associated with severity in hospitalized COVID-19 patients. Int J Mol Sci. 2021;22:4794. (PMID: 33946479812448210.3390/ijms22094794)
Cai Y, Kim DJ, Takahashi T, Broadhurst DI, Yan H, Ma S, Rattray NJ, Casanovas-Massana A, Israelow B, Klein J. Kynurenic acid may underlie sex-specific immune responses to COVID-19. Sci Signal. 2021. https://doi.org/10.1126/scisignal.abf8483 . (PMID: 10.1126/scisignal.abf8483342302108432948)
Turski WA, Wnorowski A, Turski GN, Turski CA, Turski L. AhR and IDO1 in pathogenesis of Covid-19 and the “Systemic AhR Activation Syndrome” translational review and therapeutic perspectives. Restor Neurol Neurosci. 2020. https://doi.org/10.3233/RNN-201042 . (PMID: 10.3233/RNN-201042325978237592680)
Lowe MM, Mold JE, Kanwar B, Huang Y, Louie A, Pollastri MP, Wang C, Patel G, Franks DG, Schlezinger J. Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production. PLoS ONE. 2014;9: e87877. (PMID: 24498387391212610.1371/journal.pone.0087877)
Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010;84:12658–64. (PMID: 20926566300435110.1128/JVI.01542-10)
Sariol A, Perlman S. SARS-CoV-2 takes its Toll. Nat Immunol. 2021;22:801–2. (PMID: 34103714823887710.1038/s41590-021-00962-w)
Manik M, Singh RK. Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19. J Med Virol. 2022;94:869–77. (PMID: 3467237610.1002/jmv.27405)
Larigot L, Juricek L, Dairou J, Coumoul X. AhR signaling pathways and regulatory functions. Biochimie Open. 2018;7:1–9. (PMID: 30003042603996610.1016/j.biopen.2018.05.001)
Neavin DR, Liu D, Ray B, Weinshilboum RM. The role of the aryl hydrocarbon receptor (AHR) in immune and inflammatory diseases. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19123851 . (PMID: 10.3390/ijms19123851305139216321643)
Hu X, Niu Y, Luo P, Xiao F, Yuan F, Yin H, Chen S, Guo F. Amino acid sensor GCN2 promotes SARS-CoV-2 receptor ACE2 expression in response to amino acid deprivation. Commun Biol. 2022;5:651. (PMID: 35778545924986810.1038/s42003-022-03609-0)
Nie X, Qian L, Sun R, Huang B, Dong X, Xiao Q, Zhang Q, Lu T, Yue L, Chen S. Multi-organ proteomic landscape of COVID-19 autopsies. Cell. 2021;184:775–91. https://doi.org/10.1016/j.cell.2021.01.004 . (PMID: 10.1016/j.cell.2021.01.004335034467794601)
Grunewald ME, Shaban MG, Mackin SR, Fehr AR, Perlman S. Murine coronavirus infection activates the aryl hydrocarbon receptor in an indoleamine 2, 3-dioxygenase-independent manner, contributing to cytokine modulation and proviral TCDD-inducible-PARP expression. J Virol. 2020. https://doi.org/10.1128/JVI.01743-19 . (PMID: 10.1128/JVI.01743-19316949607000979)
Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116:1097–100. (PMID: 3222709010.1093/cvr/cvaa078)
Turski WA, Wnorowski A, Turski GN, Turski CA, Turski L. AhR and IDO1 in pathogenesis of Covid-19 and the “Systemic AhR Activation Syndrome:” a translational review and therapeutic perspectives. Restor Neurol Neurosci. 2020;38:343–54. (PMID: 325978237592680)
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus. Treasure Island (FL): StatPearls Publishing; 2020.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e278. (PMID: 32142651710262710.1016/j.cell.2020.02.052)
McGavern DB, Kang SS. Illuminating viral infections in the nervous system. Nat Rev Immunol. 2011;11:318–29. https://doi.org/10.1038/nri2971 . (PMID: 10.1038/nri2971215089825001841)
Lee M-H, Perl DP, Nair G, Li W, Maric D, Murray H, Dodd SJ, Koretsky AP, Watts JA, Cheung V. Microvascular injury in the brains of patients with Covid-19. N Engl J Med. 2021;384:481–3. (PMID: 3337860810.1056/NEJMc2033369)
Matschke J, Lütgehetmann M, Hagel C, Sperhake JP, Schröder AS, Edler C, Mushumba H, Fitzek A, Allweiss L, Dandri M. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. The Lancet Neurology. 2020;19:919–29. (PMID: 33031735753562910.1016/S1474-4422(20)30308-2)
Stein SR, Ramelli SC, Grazioli A, Chung J-Y, Singh M, Yinda CK, Winkler CW, Sun J, Dickey JM, Ylaya K. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758–63. (PMID: 36517603974965010.1038/s41586-022-05542-y)
Crunfli F, Carregari VC, Veras FP, Silva LS, Nogueira MH, Antunes ASLM, Vendramini PH, Valença AGF, Brandão-Teles C, Zuccoli GdS. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc Natl Acad Sci. 2022;119: e2200960119. (PMID: 35951647943635410.1073/pnas.2200960119)
WHO (2022) Post COVID-19 condition (Long COVID). https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition . 2023.
(CDC) CfDCaP (2023) Long COVID or Post-COVID Conditions. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html .
Holmes E, Wist J, Masuda R, Lodge S, Nitschke P, Kimhofer T, Loo RL, Begum S, Boughton B, Yang R. Incomplete systemic recovery and metabolic phenoreversion in Post-Acute-Phase nonhospitalized COVID-19 patients: implications for assessment of Post-Acute COVID-19 syndrome. J Proteome Res. 2021. https://doi.org/10.1021/acs.jproteome.1c00224 . (PMID: 10.1021/acs.jproteome.1c00224344369028969901)
Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mulè G, Augello M, Mondatore D, Allegrini M, Cona A. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. 2022;28:611. https://doi.org/10.1016/j.cmi.2021.11.002 . (PMID: 10.1016/j.cmi.2021.11.002)
Fernández-de-Las-Peñas C, Martín-Guerrero JD, Pellicer-Valero ÓJ, Navarro-Pardo E, Gómez-Mayordomo V, Cuadrado ML, Arias-Navalón JA, Cigarán-Méndez M, Hernández-Barrera V, Arendt-Nielsen L. Female sex is a risk factor associated with long-term post-COVID related-symptoms but not with COVID-19 symptoms: the LONG-COVID-EXP-CM multicenter study. J Clin Med. 2022. https://doi.org/10.3390/jcm11020413 . (PMID: 10.3390/jcm11020413365559319787827)
Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, Elneima O, Docherty AB, Lone NI, Leavy OC. Physical cognitive and mental health impacts of COVID 19 following hospitalisation a multi centre prospective cohort study. medRxiv. 2021. https://doi.org/10.1016/S2213-2600(21)00383-0 . (PMID: 10.1016/S2213-2600(21)00383-0347040938547525)
Darley DR, Dore GJ, Cysique L, Wilhelm KA, Andresen D, Tonga K, Stone E, Byrne A, Plit M, Masters J. Persistent symptoms up to four months after community and hospital-managed SARS-CoV-2 infection. Med J Aust. 2021;214:279–80. (PMID: 33657671801423410.5694/mja2.50963)
Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11:1–12. (PMID: 10.1038/s41598-021-95565-8)
Lewthwaite H, Byrne A, Brew B, Gibson PG. Treatable traits for long COVID. Respirol. 2023;28:1005–22. (PMID: 10.1111/resp.14596)
Di Gennaro F, Belati A, Tulone O, Diella L, Fiore Bavaro D, Bonica R, Genna V, Smith L, Trott M, Bruyere O. Incidence of long COVID-19 in people with previous SARS-Cov2 infection: A systematic review and meta-analysis of 120,970 patients. Intern Emerg Med. 2023;18:1573–81. (PMID: 3644926010.1007/s11739-022-03164-w)
Hartung TJ, Neumann C, Bahmer T, Chaplinskaya-Sobol I, Endres M, Geritz J, Haeusler KG, Heuschmann PU, Hildesheim H, Hinz A. Fatigue and cognitive impairment after COVID-19: a prospective multicentre study. EClinicalMed. 2022. https://doi.org/10.1016/j.eclinm.2022.101651 . (PMID: 10.1016/j.eclinm.2022.101651)
Tana C, Bentivegna E, Cho S-J, Harriott AM, García-Azorín D, Labastida-Ramirez A, Ornello R, Raffaelli B, Beltrán ER, Ruscheweyh R. Long COVID headache. J Headache Pain. 2022;23:93. (PMID: 35915417934075910.1186/s10194-022-01450-8)
Gómez-Dabó L, Melgarejo-Martínez L, Caronna E, Pozo-Rosich P. Headache in COVID-19 and long COVID: to Know facts for clinical practice. Curr Neurol Neurosci Rep. 2023;23:551–60. (PMID: 3766549510.1007/s11910-023-01296-w)
Rodrigues AN, Dias ARN, Paranhos ACM, Silva CC, Bastos TdR, Brito BBd, da Silva NM, de Sousa EdJS, Quaresma JAS, Falcão LFM. Headache in long COVID as disabling condition: a clinical approach. Front Neurol. 2023;14:1149294. (PMID: 370340801007686110.3389/fneur.2023.1149294)
Fernández-de-las-Peñas C, Navarro-Santana M, Gómez-Mayordomo V, Cuadrado ML, García-Azorín D, Arendt-Nielsen L, Plaza-Manzano G. Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: a meta-analysis of the current literature. Eur J Neurol. 2021;28:3820–5. (PMID: 34327787844489910.1111/ene.15040)
Garcia-Azorin D, Layos-Romero A, Porta-Etessam J, Membrilla JA, Caronna E, Gonzalez-Martinez A, Mencia ÁS, Segura T, Gonzalez-García N, Díaz-de-Terán J. Post-COVID-19 persistent headache: a multicentric 9-months follow-up study of 905 patients. Cephalalgia. 2022;42:804–9. (PMID: 3516615610.1177/03331024211068074)
Tana C, Giamberardino MA, Martelletti P. Long COVID and especially headache syndromes. Curr Opin Neurol. 2023;36:168–74. (PMID: 3707864810.1097/WCO.0000000000001153)
Spekker E, Nagy-Grócz G, Vécsei L. Ion channel disturbances in migraine headache: exploring the potential role of the Kynurenine System in the context of the trigeminovascular system. Int J Mol Sci. 2023;24:16574. (PMID: 380688971070627810.3390/ijms242316574)
Liu Y-J, Li Y-L, Fang Z-H, Liao H-L, Zhang Y-Y, Lin J, Liu F, Shen J-F. NMDARs mediate peripheral and central sensitization contributing to chronic orofacial pain. Front Cell Neurosci. 2022;16: 999509. (PMID: 36238833955302910.3389/fncel.2022.999509)
Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J Clin Neurol. 2012;8:89–99. (PMID: 22787491339162410.3988/jcn.2012.8.2.89)
Suzuki K, Suzuki S, Shiina T, Kobayashi S, Hirata K. Central sensitization in migraine: a narrative review. J Pain Res. 2022. https://doi.org/10.2147/JPR.S329280 . (PMID: 10.2147/JPR.S329280361018919464439)
Stone TW, Mackay GM, Forrest CM, Clark CJ, Darlington LG. Tryptophan metabolites and brain disorders. Clin Chem Lab Med. 2003. https://doi.org/10.1515/CCLM.2003.129 . (PMID: 10.1515/CCLM.2003.12912940508)
Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, Takikawa O, Brew BJ. Characterization of the kynurenine pathway in human neurons. J Neurosci. 2007;27:12884–92. (PMID: 18032661667328010.1523/JNEUROSCI.4101-07.2007)
Curto M, Lionetto L, Negro A, Capi M, Fazio F, Giamberardino MA, Simmaco M, Nicoletti F, Martelletti P. Altered kynurenine pathway metabolites in serum of chronic migraine patients. J Headache Pain. 2016;17:1–7. (PMID: 4720620)
Urenjak J, Obrenovitch TP. Kynurenine 3-hydroxylase inhibition in rats: effects on extracellular kynurenic acid concentration and N-methyl-D-aspartate-induced depolarisation in the striatum. J Neurochem. 2000;75:2427–33. (PMID: 1108019410.1046/j.1471-4159.2000.0752427.x)
Bendtsen L. Central sensitization in tension-type headache—possible pathophysiological mechanisms. Cephalalgia. 2000;20:486–508. (PMID: 1103774610.1046/j.1468-2982.2000.00070.x)
Velling DA, Dodick DW, Muir JJ. Sustained-release niacin for prevention of migraine headache. Mayo Clin Proc. 2003. https://doi.org/10.4065/78.6.770 . (PMID: 10.4065/78.6.77012934790)
Loewendorf AI, Matynia A, Saribekyan H, Gross N, Csete M, Harrington M. Roads less traveled: sexual dimorphism and mast cell contributions to migraine pathology. Front Immunol. 2016;7: 170131. (PMID: 10.3389/fimmu.2016.00140)
Smitherman TA, Walters AB, Maizels M, Penzien DB. The use of antidepressants for headache prophylaxis. CNS Neurosci Ther. 2011;17:462–9. (PMID: 2195137010.1111/j.1755-5949.2010.00170.x)
Loder EW. Menstrual migraine: pathophysiology, diagnosis, and impact. Headache. 2006. https://doi.org/10.1111/j.1526-4610.2006.00555.x . (PMID: 10.1111/j.1526-4610.2006.00555.x17044842)
Grobler C, Maphumulo SC, Grobbelaar LM, Bredenkamp JC, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB, Pretorius E. Covid-19: the rollercoaster of fibrin (ogen), d-dimer, von willebrand factor, p-selectin and their interactions with endothelial cells, platelets and erythrocytes. Int J Mol Sci. 2020;21:5168. (PMID: 32708334740399510.3390/ijms21145168)
Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematology. 2020;7:e438–40. (PMID: 3240767210.1016/S2352-3026(20)30145-9)
Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, Kell DB. Persistent clotting protein pathology in Long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20:1–18. (PMID: 10.1186/s12933-021-01359-7)
Grobbelaar LM, Venter C, Vlok M, Ngoepe M, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB, Pretorius E. SARS-CoV-2 spike protein S1 induces fibrin (ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. 2021. Biosci Rep. https://doi.org/10.1042/BSR20210611 .
Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. 2022;479:537–59. (PMID: 3519525310.1042/BCJ20220016)
Kruger A, Vlok M, Turner S, Venter C, Laubscher GJ, Kell DB, Pretorius E. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol. 2022;21:1–23. (PMID: 10.1186/s12933-022-01623-4)
Voils SA, Shahin MH, Garrett TJ, Frye RF. Metabolomic association between venous thromboembolism in critically ill trauma patients and kynurenine pathway of tryptophan metabolism. Thromb Res. 2018;165:6–13. (PMID: 2954419910.1016/j.thromres.2018.03.003)
Pawlak K, Mysliwiec M, Pawlak D. Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients. Thromb Haemost. 2009;102:49–55. (PMID: 1957206710.1160/TH08-10-0696)
Mor A, Kalaska B, Pawlak D. Kynurenine pathway in chronic kidney disease: what’s old, what’s new, and what’s next? Int J Tryptophan Res. 2020;13:1178646920954882. (PMID: 35210786886219010.1177/1178646920954882)
Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci. 2017;20:145–55. (PMID: 28092661696001010.1038/nn.4476)
Salvo-Romero E, Stokes P, Gareau MG. Microbiota-immune interactions: from gut to brain. LymphoSign J. 2020;7:1–23. (PMID: 10.14785/lymphosign-2019-0018)
Lee J, Venna VR, Durgan DJ, Shi H, Hudobenko J, Putluri N, Petrosino J, McCullough LD, Bryan RM. Young versus aged microbiota transplants to germ-free mice: increased short-chain fatty acids and improved cognitive performance. Gut microbes. 2020;12:1814107. (PMID: 32897773775778910.1080/19490976.2020.1814107)
Zhang D, Zhou Y, Ma Y, Chen P, Tang J, Yang B, Li H, Liang M, Xue Y, Liu Y. Gut microbiota dysbiosis correlates with long COVID-19 at one-year after discharge. J Korean Med Sci. 2023. https://doi.org/10.3346/jkms.2023.38.e120 . (PMID: 10.3346/jkms.2023.38.e1203706981410111044)
O’Mahony SM, Clarke G, Borre Y, Dinan TG, Cryan J. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. 2015;277:32–48. (PMID: 2507829610.1016/j.bbr.2014.07.027)
Savitz J. The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2020;25:131–47. (PMID: 3098004410.1038/s41380-019-0414-4)
Griffin DE. Why does viral RNA sometimes persist after recovery from acute infections? PLoS Biol. 2022;20: e3001687. (PMID: 35648781919173710.1371/journal.pbio.3001687)
Gaebler C, Wang Z, Lorenzi JC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639–44. (PMID: 33461210822108210.1038/s41586-021-03207-w)
Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, Walt DR. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76:e487–90. (PMID: 3605246610.1093/cid/ciac722)
Ceulemans LJ, Khan M, Yoo S-J, Zapiec B, Van Gerven L, Van Slambrouck J, Vanstapel A, Van Raemdonck D, Vos R, Wauters E. Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19. Lancet Respir Med. 2021;9:e78–9. (PMID: 34118186818966710.1016/S2213-2600(21)00240-X)
Patterson BK, Francisco EB, Yogendra R, Long E, Pise A, Rodrigues H, Hall E, Herrera M, Parikh P, Guevara-Coto J. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front Immunol. 2022;12:5526. (PMID: 10.3389/fimmu.2021.746021)
Zadeh FH, Wilson DR, Agrawal DK. Long COVID: complications, underlying mechanisms, and treatment strategies. Arch Microbiol Immunol. 2023;7:36–61. (PMID: 3738827910310313)
Bernal KDE, Whitehurst CB. Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients. Virus Res. 2023;334: 199157. (PMID: 373648151029273910.1016/j.virusres.2023.199157)
Manoharan S, Ying LY. Epstein Barr virus reactivation during COVID-19 hospitalization significantly increased mortality/death in SARS-CoV-2 (+)/EBV (+) than SARS-CoV-2 (+)/EBV (−) Patients: a comparative meta-analysis. Int J Clinic Pract. 2023. https://doi.org/10.1155/2023/1068000 . (PMID: 10.1155/2023/1068000)
Hashimoto K. Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: the role of Epstein-Barr virus and the gut–brain axis. Mol Psychiatr. 2023;28:4968–76. https://doi.org/10.1038/s41380-023-02161-5 . (PMID: 10.1038/s41380-023-02161-5)
Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10:763. (PMID: 34204243823397810.3390/pathogens10060763)
Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, Tabachnikova A, Greene K, Tabacof L, Malik AA. Distinguishing features of Long COVID identified through immune profiling. Nature. 2023;623:139–48. (PMID: 377485141062009010.1038/s41586-023-06651-y)
Liu W-l, Lin Y-h, Xiao H, Xing S, Chen H, Chi P-d, Zhang G. Epstein-Barr virus infection induces indoleamine 2, 3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-κB pathways: impairment in T cell functions. J Virol. 2014;88:6660–71. (PMID: 24696473405436410.1128/JVI.03678-13)
Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri F, Rovere-Querini P. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594–600. (PMID: 32738287739074810.1016/j.bbi.2020.07.037)
Krishnamoorthy Y, Nagarajan R, Saya GK, Menon V. Prevalence of psychological morbidities among general population, healthcare workers and COVID-19 patients amidst the COVID-19 pandemic: a systematic review and meta-analysis. Psychiatry Res. 2020;293: 113382. (PMID: 32829073741729210.1016/j.psychres.2020.113382)
Naidu SB, Shah AJ, Saigal A, Smith C, Brill SE, Goldring J, Hurst JR, Jarvis H, Lipman M, Mandal S. The high mental health burden of “Long COVID” and its association with on-going physical and respiratory symptoms in all adults discharged from hospital. Eur Respir J. 2021;57:2004364. (PMID: 33795319801564510.1183/13993003.04364-2020)
Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Int J Biochem Cell Biol. 2002;13:455–81.
Essa MM, Hamdan H, Chidambaram SB, Al-Balushi B, Guillemin GJ, Ojcius DM, Qoronfleh MW. Possible role of tryptophan and melatonin in COVID-19. Int J Tryptophan Res. 2020;13:1178646920951832. (PMID: 32913393744375110.1177/1178646920951832)
Marciniak E, Faivre E, Dutar P, Pires CA, Demeyer D, Caillierez R, Laloux C, Buée L, Blum D, Humez S. The Chemokine MIP-1α/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory. Sci Rep. 2015;5:1–11. (PMID: 10.1038/srep15862)
Sforzini L, Nettis MA, Mondelli V, Pariante CM. Inflammation in cancer and depression: a starring role for the kynurenine pathway. Psychopharmacology. 2019;236:2997–3011. (PMID: 308067436820591)
Guo Y, Cai H, Chen L, Liang D, Yang R, Dang R, Jiang P. Quantitative profiling of neurotransmitter abnormalities in the hippocampus of rats treated with lipopolysaccharide: focusing on kynurenine pathway and implications for depression. J Neuroimmunol. 2016;295:41–6. (PMID: 2723534710.1016/j.jneuroim.2016.04.006)
Serafini G, Adavastro G, Canepa G, Capobianco L, Conigliaro C, Pittaluga F, Belvederi Murri M, Valchera A, De Berardis D, Pompili M. Abnormalities in kynurenine pathway metabolism in treatment-resistant depression and suicidality: a systematic review. CNS Neurol Disord Drug Targets. 2017;16:440–53. (PMID: 2841292210.2174/1871527316666170413110605)
Haroon E, Welle JR, Woolwine BJ, Goldsmith DR, Baer W, Patel T, Felger JC, Miller AH. Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. Neuropsychopharmacol. 2020;45:998–1007. (PMID: 10.1038/s41386-020-0607-1)
Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein H-G, Sarnyai Z, Mawrin C, Brisch R, Bielau H, zu Schwabedissen LM,. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation. 2011;8:1–9. (PMID: 10.1186/1742-2094-8-94)
Savitz J, Ford BN, Yeh H-W, Akeman E, Cosgrove K, Clausen AN, Martell C, Kirlic N, Santiago J, Teague TK. Behavioral activation therapy for depression is associated with a reduction in the concentration of circulating quinolinic acid. Psychol Med. 2020;52:1–10.
Dantzer R, O’connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56. (PMID: 18073775291927710.1038/nrn2297)
Myint A-M, Kim YK, Verkerk R, Scharpé S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007;98:143–51. (PMID: 1695240010.1016/j.jad.2006.07.013)
Zhou X, Hollern D, Liao J, Andrechek E, Wang H. NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis. 2013;4:e560–e560. (PMID: 23538441361574610.1038/cddis.2013.82)
Vaváková M, Ďuračková Z, Trebatická J. Markers of oxidative stress and neuroprogression in depression disorder. Oxid Med Cell Longev. 2015;2015: 898393. (PMID: 26078821445328010.1155/2015/898393)
Ruiz NAL, Del Ángel DS, Olguín HJ, Silva ML. Neuroprogression: the hidden mechanism of depression. Neuropsychiatr Dis Treat. 2018;14:2837. (PMID: 30464468621458710.2147/NDT.S177973)
Tenforde MW, Kim SS, Lindsell CJ, Rose EB, Shapiro NI, Files DC, Gibbs KW, Erickson HL, Steingrub JS, Smithline HA. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March–June 2020. Morb Mortal Wkly Rep. 2020;69:993–8. (PMID: 10.15585/mmwr.mm6930e1)
Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–5. (PMID: 32644129734909610.1001/jama.2020.12603)
Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, O’Connor L, Leavy D, O’Brien K, Dowds J. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS ONE. 2020;15: e0240784. (PMID: 33166287765225410.1371/journal.pone.0240784)
Komaroff AL. The Tragedy of the Post-COVID “Long Haulers.” Harvard Health Letter: Harvard Health Publishng, Harvard Medical School; 2021.
Bornstein SR, Voit-Bak K, Donate T, Rodionov RN, Gainetdinov RR, Tselmin S, Kanczkowski W, Müller GM, Achleitner M, Wang J. Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis? Mol Psychiatry. 2021;27:1–4.
Dibble JJ, McGrath SJ, Ponting CP. Genetic risk factors of ME/CFS: a critical review. Hum Mol Genet. 2020;29:R117–24. (PMID: 32744306753051910.1093/hmg/ddaa169)
Mona Dehhaghi HKSP, Kavyani B, Heng B, Tan V, Braidy N, Guillemin GJ. The role of Kynurenine pathway and NAD + metabolism in myalgic Encephalomyelitis/Chronic fatigue syndrome. Aging Dis. 2022;13:698–711. (PMID: 35656104911691710.14336/AD.2021.0824)
Aoun Sebaiti M, Hainselin M, Gounden Y, Sirbu CA, Sekulic S, Lorusso L, Nacul L, Authier FJ. Systematic review and meta-analysis of cognitive impairment in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Sci Rep. 2022;12:1–17. (PMID: 10.1038/s41598-021-04764-w)
McGregor NR, Armstrong CW, Lewis DP, Gooley PR. Post-exertional malaise is associated with hypermetabolism, hypoacetylation and purine metabolism deregulation in ME/CFS cases. Diagnostics. 2019;9:70. (PMID: 31277442678767010.3390/diagnostics9030070)
Braidy N, Guillemin GJ, Grant R. Effects of kynurenine pathway inhibition on NAD+ metabolism and cell viability in human primary astrocytes and neurons. Int J Tryptophan Res. 2011. https://doi.org/10.4137/IJTR.S7052 . (PMID: 10.4137/IJTR.S7052220846013195218)
Moffett JR, Arun P, Puthillathu N, Vengilote R, Ives JA, Badawy AA, Namboodiri AM. Quinolinate as a marker for kynurenine metabolite formation and the unresolved question of NAD+ synthesis during inflammation and infection. Front Immunol. 2020. https://doi.org/10.3389/fimmu.2020.00031 . (PMID: 10.3389/fimmu.2020.00031321535567047773)
Schreiber V, Amé J-C, Dollé P, Schultz I, Rinaldi B, Fraulob V, Ménissier-de Murcia J, de Murcia G. Poly (ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem. 2002;277:23028–36. (PMID: 1194819010.1074/jbc.M202390200)
Dash S, Dash C, Pandhare J. Therapeutic significance of microRNA-mediated regulation of PARP-1 in SARS-CoV-2 infection. Noncoding RNA. 2021;7:60. (PMID: 346982618544662)
Escarcega RD, Honarpisheh P, Colpo GD, Ahnstedt HW, Couture L, Juneja S, Torres G, Ortiz GJ, Sollome J, Tabor N. Sex differences in global metabolomic profiles of COVID-19 patients. Cell Death Dis. 2022;13:461. (PMID: 35568706910698810.1038/s41419-022-04861-2)
Danlos F-X, Grajeda-Iglesias C, Durand S, Sauvat A, Roumier M, Cantin D, Colomba E, Rohmer J, Pommeret F, Baciarello G. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death Dis. 2021;12:258. (PMID: 33707411794817210.1038/s41419-021-03540-y)
Mangge H, Herrmann M, Meinitzer A, Pailer S, Curcic P, Sloup Z, Holter M, Prüller F. Increased kynurenine indicates a fatal course of COVID-19. Antioxidants. 2021;10:1960. https://doi.org/10.3390/antiox10121960 . (PMID: 10.3390/antiox10121960349430638750518)
Bizjak DA, Stangl M, Börner N, Bösch F, Durner J, Drunin G, Buhl J-L, Abendroth D. Kynurenine serves as useful biomarker in acute, long-and post-COVID-19 diagnostics. Front Immunol. 2022;13:1004545. (PMID: 36211365953776910.3389/fimmu.2022.1004545)
Cihan M, Doğan Ö, Ceran Serdar C, Altunçekiç Yıldırım A, Kurt C, Serdar MA. Kynurenine pathway in coronavirus disease (COVID-19): potential role in prognosis. J Clin Lab Anal. 2022;36: e24257. (PMID: 35092710890603510.1002/jcla.24257)
معلومات مُعتمدة: Macquarie University Research Excellence Scholarship Macquarie University; Macquarie University Research Excellence Scholarship Macquarie University; APP1176660 National Health and Medical Research Council
فهرسة مساهمة: Keywords: COVID-19; Kynurenine pathway; Long COVID; Neurological manifestations; SARS-CoV-2; Tryptophan
تواريخ الأحداث: Date Created: 20240527 Latest Revision: 20240527
رمز التحديث: 20240528
DOI: 10.1007/s15010-024-02293-y
PMID: 38802702
قاعدة البيانات: MEDLINE
الوصف
تدمد:1439-0973
DOI:10.1007/s15010-024-02293-y